Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3871-3880 Newer>

The Motley Fool July 18, 2007 Brian Orelli	Pain-Free Payday for DURECT Results from a trial take it one step closer to possible approval for a local anesthetic. Because the platform can be used with different types of drugs, DURECT could try to win additional partnerships.
The Motley Fool July 18, 2007 Rich Duprey	The Word on Earnings at BSD Medical Sales improved a bit at the cancer treatment firm, but that's not in its many press releases. It looks like BSD Medical's investors could get frustrated quickly.
The Motley Fool July 18, 2007 Brian Lawler	More Misery for Neurochem It's hard to find another drug developer that has mishandled its correspondence with investors about its drug candidates as badly as Neurochem has over the past year.
The Motley Fool July 17, 2007 Brian Orelli	An Investor's Guide to the New PDUFA It's important for investors in drug companies to keep up with the latest clinical trial news, but policy changes in Washington can affect companies' bottom lines just as much.
The Motley Fool July 17, 2007 Andrew R. Vaino	Problems Posed for Pozen If its latest drug isn't approved, the pharmaceutical's stock will clearly tank. Any benefits stemming from the drug's successful approval are harder to gauge.
The Motley Fool July 17, 2007 Brian Lawler	QLT Stays the Course Sales of QLT's Visudyne, a drug to treat macular degeneration, continue to plummet due to competition. QLT plans to try to resuscitate.
The Motley Fool July 17, 2007 Ryan Fuhrmann	Diagnosing J&J's Product Diversity Health-care giant Johnson & Johnson's blues may indicate trouble ahead for competitors. Investors, take note.
Chemistry World July 16, 2007 Karen Harries-Rees	Hallucinogenic Drug in the Clinic A trial to determine whether patients with anxiety relating to advanced-stage illnesses can be safely given LSD-assisted psychotherapy and whether it improves their anxiety symptoms has been approved by a Swiss ethics committee.
The Motley Fool July 16, 2007 Brian Lawler	Idenix Gets Stopped It's been a bad two months for Idenix Pharmaceuticals. First, negative data for its hepatitis drug candidate, valopicitabine; now the FDA has put a stop to all testing of the drug.
The Motley Fool July 16, 2007 Brian Orelli	Ventana Says No, We Can't Talk In many ways, Ventana is actually a perfect match for Roche. But for now, this hostile takeover bid is stalled. Investors, take note.
<Older 3871-3880 Newer> Return to current articles.